{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:21:00Z","timestamp":1768407660541,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Early heart failure prevention is central in patients with type 2 diabetes, and mineralocorticoid receptor antagonists (MRAs) have shown to improve prognosis. We investigated the effect of high-dose MRA, eplerenone, on cardiac function and structure in patients with type 2 diabetes and established or increased risk of cardiovascular disease but without heart failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In the current randomized, placebo-controlled clinical trial, 140 patients with high-risk type 2 diabetes were randomized to high-dose eplerenone (100\u2013200\u00a0mg daily) or placebo as add-on to standard care for 26\u00a0weeks. Left ventricular systolic and diastolic function, indexed left ventricular mass (LVMi), and global longitudinal strain (GLS) were assessed using echocardiography at baseline and after 26\u00a0weeks of treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the included patients, 138 (99%) had an echocardiography performed at least once. Baseline early diastolic in-flow velocity (E-wave) indexed by mitral annulus velocity (e\u2019) was mean (SD) 11.1 (0.5), with 31% of patients reaching above 12. No effect of treatment on diastolic function was observed measured by E\/e\u2019 (0.0, 95%CI [-1.2 to 1.2], <jats:italic>P<\/jats:italic>\u2009=\u20090.992) or E\/A (-0.1, 95%CI [-0.2 to 0.0], <jats:italic>P<\/jats:italic>\u2009=\u20090.191). Mean left ventricular ejection fraction (LVEF) at baseline was 59.0% (8.0). No improvement in systolic function was observed when comparing groups after 26\u00a0weeks (LVEF: 0.9, 95%CI [-1.1 to 2.8], <jats:italic>P<\/jats:italic>\u2009=\u20090.382; GLS: -0.4%, 95%CI [-1.5 to 0.6], <jats:italic>P<\/jats:italic>\u2009=\u20090.422), nor in LVMi (-3.8\u00a0g\/m<jats:sup>2<\/jats:sup> 95%CI [-10.2 to 2.7], <jats:italic>P<\/jats:italic>\u2009=\u20090.246).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In the present echo sub-study, no change in left ventricular function was observed following high-dose MRA therapy in patients with type 2 diabetes when evaluated by conventional echocardiography.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Date of registration 25\/08\/2015 (EudraCT number: 2015\u2013002,519-14).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-023-03183-1","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T10:03:30Z","timestamp":1680257010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Niels","family":"H. Brandt-Jacobsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Louise","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon J.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Dalsgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kumler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Faber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Kistorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"3183_CR1","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/dom.14074","volume":"22","author":"KI Birkeland","year":"2020","unstructured":"Birkeland KI, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GCM, et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. Diabetes, Obes Metab. 2020;22:1607\u201318. https:\/\/doi.org\/10.1111\/dom.14074.","journal-title":"Diabetes, Obes Metab"},{"key":"3183_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255\u2013323. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486.","journal-title":"Eur Heart J"},{"key":"3183_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1053-2498(01)00776-8","volume":"21","author":"SA Hunt","year":"2002","unstructured":"Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC\/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Hear Lung Transplant. 2002;21:189\u2013203. https:\/\/doi.org\/10.1016\/S1053-2498(01)00776-8.","journal-title":"J Hear Lung Transplant"},{"key":"3183_CR4","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/dom.13583","volume":"21","author":"J Jensen","year":"2019","unstructured":"Jensen J, Schou M, Kistorp C, Faber J, Hansen TW, Jensen MT, et al. Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes. Diabetes, Obes Metab. 2019;21:736\u201340. https:\/\/doi.org\/10.1111\/dom.13583.","journal-title":"Diabetes, Obes Metab"},{"key":"3183_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2017.00160","volume":"8","author":"R Altara","year":"2017","unstructured":"Altara R, Giordano M, Nord\u00e9n ES, Cataliotti A, Kurdi M, Bajestani SN, et al. Targeting obesity and diabetes to treat heart failure with preserved ejection fraction. Front Endocrinol (Lausanne). 2017;8:1\u201313. https:\/\/doi.org\/10.3389\/fendo.2017.00160.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3183_CR6","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S0140-6736(18)31808-7","volume":"393","author":"P Rossignol","year":"2019","unstructured":"Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. Lancet. 2019;393:1034\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(18)31808-7.","journal-title":"Lancet"},{"key":"3183_CR7","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.2337\/dc19S010","volume":"42","author":"D Care","year":"2019","unstructured":"Care D, Suppl SS. 10. Cardiovascular disease and risk management: Standards of medical care in diabetesd - 2019. Diabetes Care. 2019;42:S103-23. https:\/\/doi.org\/10.2337\/dc19S010.","journal-title":"Diabetes Care."},{"key":"3183_CR8","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1096\/fj.04-2263com","volume":"18","author":"S Sharma","year":"2004","unstructured":"Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004;18:1692\u2013700. https:\/\/doi.org\/10.1096\/fj.04-2263com.","journal-title":"FASEB J"},{"key":"3183_CR9","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1161\/HYPERTENSIONAHA.114.04912","volume":"65","author":"SB Bender","year":"2015","unstructured":"Bender SB, DeMarco VG, Padilla J, Jenkins NT, Habibi J, Garro M, et al. Mineralocorticoid Receptor Antagonism Treats Obesity-Associated Cardiac Diastolic Dysfunction. Hypertension. 2015;65:1082\u20138. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.04912.","journal-title":"Hypertension"},{"key":"3183_CR10","doi-asserted-by":"publisher","first-page":"e110950","DOI":"10.1371\/journal.pone.0110950","volume":"9","author":"C Li","year":"2014","unstructured":"Li C, Zhang YY, Frieler RA, Zheng XJ, Zhang WC, Sun XN, et al. Myeloid Mineralocorticoid Receptor Deficiency Inhibits Aortic Constriction-Induced Cardiac Hypertrophy in Mice. PLoS One. 2014;9:e110950. https:\/\/doi.org\/10.1371\/journal.pone.0110950.","journal-title":"PLoS One."},{"key":"3183_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/1475-2840-12-172","volume":"12","author":"E Ram\u00edrez","year":"2013","unstructured":"Ram\u00edrez E, Klett-Mingo M, Ares-Carrasco S, Picatoste B, Ferrarini A, Rup\u00e9rez FJ, et al. Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. Cardiovasc Diabetol. 2013;12:172. https:\/\/doi.org\/10.1186\/1475-2840-12-172.","journal-title":"Cardiovasc Diabetol."},{"key":"3183_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. N Engl J Med. 1999;341:709\u201317. https:\/\/doi.org\/10.1056\/NEJM199909023411001.","journal-title":"N Engl J Med"},{"key":"3183_CR13","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med. 2003;348:1309\u201321. https:\/\/doi.org\/10.1056\/NEJMoa030207.","journal-title":"N Engl J Med"},{"key":"3183_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med. 2011;364:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492.","journal-title":"N Engl J Med"},{"key":"3183_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10741-018-9758-0","volume":"24","author":"CJ Kapelios","year":"2019","unstructured":"Kapelios CJ, Murrow JR, N\u00fchrenberg TG, Montoro Lopez MN. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev. 2019;24:367\u201377. https:\/\/doi.org\/10.1007\/s10741-018-9758-0.","journal-title":"Heart Fail Rev"},{"key":"3183_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1161\/CIRCHEARTFAILURE.112.000074","volume":"6","author":"X Li","year":"2013","unstructured":"Li X, Qi Y, Li Y, Zhang S, Guo S, Chu S, et al. Impact of Mineralocorticoid Receptor Antagonists on Changes in Cardiac Structure and Function of Left Ventricular Dysfunction. Circ Hear Fail. 2013;6:156\u201365. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.112.000074.","journal-title":"Circ Hear Fail"},{"key":"3183_CR17","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/ejhf.792","volume":"19","author":"A Olivier","year":"2017","unstructured":"Olivier A, Pitt B, Girerd N, Lamiral Z, Machu J-L, McMurray JJV, et al. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. Eur J Heart Fail. 2017;19:1186\u201397. https:\/\/doi.org\/10.1002\/ejhf.792.","journal-title":"Eur J Heart Fail."},{"key":"3183_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2337\/dc17-0755","volume":"41","author":"PB Sandesara","year":"2018","unstructured":"Sandesara PB, O\u2019Neal WT, Kelli HM, Samman-Tahhan A, Hammadah M, Quyyumi AA, et al. The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction. Diabetes Care. 2018;41:150\u20135. https:\/\/doi.org\/10.2337\/dc17-0755.","journal-title":"Diabetes Care"},{"key":"3183_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709\u201316. https:\/\/doi.org\/10.1016\/S0895-7061(02)02957-6.","journal-title":"Am J Hypertens"},{"key":"3183_CR20","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of Eplerenone, Enalapril, and Eplerenone\/Enalapril in Patients With Essential Hypertension and Left Ventricular Hypertrophy. Circulation. 2003;108:1831\u20138. https:\/\/doi.org\/10.1161\/01.CIR.0000091405.00772.6E.","journal-title":"Circulation"},{"key":"3183_CR21","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1111\/dom.13809","volume":"21","author":"ML Johansen","year":"2019","unstructured":"Johansen ML, Schou M, Rossignol P, Holm MR, Rasmussen J, Brandt N, et al. Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial (MIRAD trial). Diabetes, Obes Metab. 2019;21:2305\u201314. https:\/\/doi.org\/10.1111\/dom.13809.","journal-title":"Diabetes, Obes Metab"},{"key":"3183_CR22","doi-asserted-by":"publisher","first-page":"101190","DOI":"10.1016\/j.diabet.2020.08.005","volume":"47","author":"NH Brandt-Jacobsen","year":"2021","unstructured":"Brandt-Jacobsen NH, Johansen ML, Rasmussen J, Forman JL, Holm MR, Faber J, et al. Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial. Diabetes Metab. 2021;47:101190. https:\/\/doi.org\/10.1016\/j.diabet.2020.08.005.","journal-title":"Diabetes Metab."},{"key":"3183_CR23","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1007\/s00125-006-0359-4","volume":"49","author":"L Tarnow","year":"2006","unstructured":"Tarnow L, Gall M-A, Hansen BV, Hovind P, Parving H-H. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia. 2006;49:2256\u201362. https:\/\/doi.org\/10.1007\/s00125-006-0359-4.","journal-title":"Diabetologia"},{"key":"3183_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1-39.e14. https:\/\/doi.org\/10.1016\/j.echo.2014.10.003.","journal-title":"J Am Soc Echocardiogr"},{"key":"3183_CR25","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","volume":"110","author":"RB Devereux","year":"2004","unstructured":"Devereux RB, Dahl\u00f6f B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by Losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004;110:1456\u201362. https:\/\/doi.org\/10.1161\/01.CIR.0000141573.44737.5A.","journal-title":"Circulation"},{"key":"3183_CR26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/1479164116653342","volume":"13","author":"AMN Walker","year":"2016","unstructured":"Walker AMN, Patel PA, Rajwani A, Groves D, Denby C, Kearney L, et al. Diabetes mellitus is associated with adverse structural and functional cardiac remodelling in chronic heart failure with reduced ejection fraction. Diabetes Vasc Dis Res. 2016;13:331\u201340. https:\/\/doi.org\/10.1177\/1479164116653342.","journal-title":"Diabetes Vasc Dis Res"},{"key":"3183_CR27","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","volume":"142","author":"FR Mc Causland","year":"2020","unstructured":"Mc Causland FR, Lefkowitz MP, Claggett B, Anavekar NS, Senni M, Gori M, et al. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation. 2020;142:1236\u201345. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.047643.","journal-title":"Circulation"},{"key":"3183_CR28","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1016\/j.jacc.2019.09.063","volume":"74","author":"AM Shah","year":"2019","unstructured":"Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, et al. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2019;74:2858\u201373. https:\/\/doi.org\/10.1016\/j.jacc.2019.09.063.","journal-title":"J Am Coll Cardiol"},{"key":"3183_CR29","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","volume":"4","author":"W Kosmala","year":"2011","unstructured":"Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O\u2019Moore-Sullivan T, Marwick TH. A Randomized Study of the Beneficial Effects of Aldosterone Antagonism on LV Function, Structure, and Fibrosis Markers in Metabolic Syndrome. JACC Cardiovasc Imaging. 2011;4:1239\u201349. https:\/\/doi.org\/10.1016\/j.jcmg.2011.08.014.","journal-title":"JACC Cardiovasc Imaging"},{"key":"3183_CR30","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1093\/ehjci\/jeu013","volume":"15","author":"CL Jellis","year":"2014","unstructured":"Jellis CL, Sacre JW, Wright J, Jenkins C, Haluska B, Jeffriess L, et al. Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy. Eur Hear J - Cardiovasc Imaging. 2014;15:776\u201386. https:\/\/doi.org\/10.1093\/ehjci\/jeu013.","journal-title":"Eur Hear J - Cardiovasc Imaging"},{"key":"3183_CR31","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, et al. Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction. JAMA. 2013;309:781. https:\/\/doi.org\/10.1001\/jama.2013.905.","journal-title":"JAMA"},{"key":"3183_CR32","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jchf.2021.05.014","volume":"9","author":"G Vergaro","year":"2021","unstructured":"Vergaro G, Gentile F, Meems LMG, Aimo A, Januzzi JL, Richards AM, et al. NT-proBNP for Risk Prediction in Heart Failure. JACC Hear Fail. 2021;9:653\u201363. https:\/\/doi.org\/10.1016\/j.jchf.2021.05.014.","journal-title":"JACC Hear Fail"},{"key":"3183_CR33","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/NEJMc1612601","volume":"376","author":"S de Denus","year":"2017","unstructured":"de Denus S, O\u2019Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, et al. Spironolactone Metabolites in TOPCAT \u2014 New Insights into Regional Variation. N Engl J Med. 2017;376:1690\u20132. https:\/\/doi.org\/10.1056\/NEJMc1612601.","journal-title":"N Engl J Med"},{"key":"3183_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circulation. 2015;131:34\u201342. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013255.","journal-title":"Circulation"},{"key":"3183_CR35","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","volume":"42","author":"JGF Cleland","year":"2021","unstructured":"Cleland JGF, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, et al. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u2018OMics\u2019 in AGEing (HOMAGE) randomized clinical trial. Eur Heart J. 2021;42:684\u201396. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa758.","journal-title":"Eur Heart J"},{"key":"3183_CR36","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383:2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"key":"3183_CR37","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385:2252\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2110956.","journal-title":"N Engl J Med"},{"key":"3183_CR38","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777.","journal-title":"Eur Heart J"},{"issue":"12","key":"3183_CR39","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390. https:\/\/doi.org\/10.2337\/dci22-0027.","journal-title":"Diabetes Care"},{"key":"3183_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.11.010","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP, Verdonschot J, Wang P, Pizard A, Collier T, Ahmed FZ, et al. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC Hear Fail. 2021. https:\/\/doi.org\/10.1016\/j.jchf.2020.11.010.","journal-title":"JACC Hear Fail"},{"key":"3183_CR41","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/ajh.2010.80","volume":"23","author":"SD Pierdomenico","year":"2010","unstructured":"Pierdomenico SD, Cuccurullo F. Risk Reduction After Regression of Echocardiographic Left Ventricular Hypertrophy in Hypertension: A Meta-Analysis. Am J Hypertens. 2010;23:876\u201381. https:\/\/doi.org\/10.1038\/ajh.2010.80.","journal-title":"Am J Hypertens"},{"issue":"36","key":"3183_CR42","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1093\/eurheartj\/ehaa419","volume":"41","author":"AJM Brown","year":"2020","unstructured":"Brown AJM, Gandy S, McCrimmon R, Houston JG, Struthers AD, Lang CC. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. Eur Heart J. 2020;41(36):3421\u201332. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa419.","journal-title":"Eur Heart J."},{"key":"3183_CR43","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, et al. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019;140:1693\u2013702. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.042375.","journal-title":"Circulation"},{"key":"3183_CR44","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jchf.2021.02.016","volume":"9","author":"NH Brandt-Jacobsen","year":"2021","unstructured":"Brandt-Jacobsen NH, Lav Madsen P, Johansen ML, Rasmussen JJ, Forman JL, Holm MR, et al. Mineralocorticoid Receptor Antagonist Improves Cardiac Structure in Type 2 Diabetes. JACC Hear Fail. 2021;9:550\u20138. https:\/\/doi.org\/10.1016\/j.jchf.2021.02.016.","journal-title":"JACC Hear Fail"},{"key":"3183_CR45","doi-asserted-by":"publisher","first-page":"107987","DOI":"10.1016\/j.pharmthera.2021.107987","volume":"231","author":"A Mamazhakypov","year":"2022","unstructured":"Mamazhakypov A, Hein L, Lother A. Mineralocorticoid receptors in pulmonary hypertension and right heart failure: From molecular biology to therapeutic targeting. Pharmacol Ther. 2022;231:107987. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107987.","journal-title":"Pharmacol Ther."},{"key":"3183_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-016-0333-5","volume":"15","author":"JH Liu","year":"2016","unstructured":"Liu JH, Chen Y, Yuen M, Zhen Z, Chan CWS, Lam KSL, et al. Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2016;15:1\u20137. https:\/\/doi.org\/10.1186\/s12933-016-0333-5.","journal-title":"Cardiovasc Diabetol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03183-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-023-03183-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03183-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T10:07:18Z","timestamp":1680257238000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-023-03183-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3183"],"URL":"https:\/\/doi.org\/10.1186\/s12872-023-03183-1","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]},"assertion":[{"value":"18 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Regional Scientific Ethics Committee (H-15009313), the Danish Data Protection Agency (2012\u201358-0004), participants supplied written and verbal informed consent, and the study was completed in accordance with the Declaration of Helsinki. The trial was conducted and monitored by an independent unit from Copenhagen, Denmark, in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice. The trial was registered at the European Clinical Trials Register (Date of registration: 25\/08\/2015, EudraCT number: 2015\u2013002519-14). Due to an inability of performing NMR-imaging on the required patients\u00a0needed to adhere to the initial power calculation of the primary endpoint, liver fat, an amendment was added to the protocol allowing the inclusion of an additional 10 patients. The amendment was not influenced by conditions concerning the reported endpoints in the present manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.K. has served on scientific advisory panels and\/or received speaker fees from Boehringer Ingelheim, Merck Shape and Dome, Astra Zeneca, Amgen, Novartis, Novo Nordisk and Shire. P.R. reports personal fees from Ablative Solutions, AstraZeneca, Bayer, Boehringer-Ingelheim, Corvidia, CVRx, Fresenius, G3P (stocks), Grunenthal, Idorsia, KBP, Novartis, NovoNordisk, Relypsa, Sanofi, Sequana Medical, Servier, Stealth Peptides, Vifor, Vifor Fresenius Medical Care Renal Pharma; and Cofounder: CardioRenal, outside the submitted work. T.K has served on scientific advisory panels and\/or received speaker fees from Boehringer Ingelheim, Merck Shape and Dome, Astra Zeneca, Bristol Meyer Squibb, Bayer, and J.F. has served on scientific advisory boards at Merck Shape and Dome, Astra Zeneca, Novo Nordisk and Otsuka. N.B.J, M.L.J., J.R., M.D., and M.S. have nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}